Midatech has announced an extension of the Q-Sphera R&D Collaboration (‘the Collaboration’) that was originally detailed on 21 July 2020, while also disclosing that the previously unnamed party is, in
TPI provides its latest research note on Midatech Pharma plc (MTPH.L)
Midatech has announced it has raised £10 million (gross) new funding through a UK equity placing (‘the Placing’) to new and existing UK investors at an issue price of 28.5p/share.
Midatech Pharma PLC (MTPH.L) Breakthrough data using Q-Sphera technology
Breakthrough data on the successful encapsulation of a biologic using Q-Sphera technology Significant progress across multiple other R&D programmes
TPI provides its latest research note on Midatech Pharma plc (MTPH.L).
Midatech yesterday published a business update which included a number of elements of positive news. These included:
Midatech Pharma PLC (MTPH.L) Headline Results of MTX110 Phase I DIPG Study
Phase II Dose Confirmed and Encouraging Survival Data
TPI provides its latest research note on Midatech Pharma plc (MTPH.L).
Midatech has today announced encouraging headline results from a Phase I study at the University of California, San Francisco (‘UCSF’) in patients with the orphan condition, Diffuse Intrinsic Pontine Glioma
TPI provides its latest research note on Midatech Pharma plc (MTPH.L).
Midatech has today announced its signing of further research collaboration, this time with an unnamed ‘global pharmaceutical’ group that wishes to utilise its Q-Sphera™ platform in order to improve/optimise the
Midatech Pharma PLC (MTPH.L) Collaboration for the Q-Sphera platform
Midatech Pharma’s next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company.